Proactive Investors - Run By Investors For Investors

Cyclacel looking to begin proof of concept study in CLL

CEO Spiro Rombotis from Cyclacel Pharmaceuticals (NASDAQ:CYCC) says the team is planning to initiate a translational clinical study to evaluate their drug CYC065 in combination with venetoclax in chronic lymphocytic leukemia (CLL).

Rombotis says they expect to start enrolling patients in the first half and expects an output of data by the end of 2019. Rombotis says their $26 mln in cash will take them to the end of 2019, enough to hit the company's major milestones.

 
View full CYCCP profile View Profile

Cyclacel Pharmaceuticals Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use